

1 **tame: An R package for identifying clusters of medication use**  
2 **based on dose, timing and type of medication**

3 Anna Laksafoss<sup>1\*</sup>, Jan Wohlfahrt<sup>2</sup>, Anders Hviid<sup>1,3</sup>

4

5 <sup>1</sup> Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.

6 <sup>2</sup> Danish Cancer Institute, Cancer Epidemiology and Surveillance, Strandboulevarden 49, 2100  
7 Copenhagen, Denmark

8 <sup>3</sup> Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of  
9 Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen,  
10 Denmark

11

12

13

14 \*Corresponding Author: Anna Laksafoss

15 Figures: 3

16 Code Chunks: 3

17 Supplementary Materials: 8 supplementary sections, including 7 tables and 2 figures

18 Word Count – Abstract: 195 words

19 Word Count – Main: 3509 words

## 20 **ABSTRACT**

21 Simplified exposure classifications, such as ever exposed versus never exposed, are commonly used  
22 in pharmacoepidemiology. However, this simplification may obscure complex use patterns relevant  
23 to researchers. We introduce tame, an R package that offers a novel method for classifying  
24 medication use patterns, capturing complexities such as timing, dose, and concurrent medication use  
25 in real-world data. The core innovation of tame is its bespoke distance measure, which identifies  
26 complex clusters in medication use and is highly adaptable, allowing customization based on the  
27 Anatomical Therapeutic Chemical (ATC) Classification System, medication timing, and dose. By  
28 prioritizing a robust distance measure, tame ensures accurate and meaningful clustering, enabling  
29 researchers to uncover intricate patterns within their data. The package also includes tools for  
30 visualizing and applying these clusters to new datasets. In a national Danish cohort study, tame  
31 identified nuanced antidepressant use patterns before and during pregnancy, demonstrating its  
32 capability to detect complex trends. tame is available on the Comprehensive R Archive Network at  
33 [<https://CRAN.R-project.org/package=tame>] under an MIT license, with a development version on  
34 GitHub at [<https://github.com/Laksafoss/tame>]. tame enhances medication use classification by  
35 detecting complex interactions and offering insights into real-world medication usage, thus  
36 improving stratification in epidemiological studies.

### 37 **Key Words**

38 Polypharmacy, medication trajectories, unsupervised machine learning, clustering, R package,  
39 epidemiology

## 40 INTRODUCTION

41 Developments in the field of machine learning, improvements in computing power, and the  
42 increasing richness of data now make it feasible to conduct more nuanced analyses of medication  
43 patterns. Central to these analyses is the construction of effective distance measures, which are  
44 critical in determining the success of clustering methods. A number of recent studies have explored  
45 data-driven approaches to exposure classification. For example, methods such as longitudinal k-  
46 means and latent class analysis have been applied to longitudinal medication data to classify  
47 exposure trajectories [1, 2, 3, 4], and these methods have been implemented in software such as the  
48 R-packages `km1` [5, 6] and `lcm1` [7]. However, these existing methods exhibit significant limitations.  
49 Primarily, they focus exclusively on drug exposure timing, which restricts their ability to account for  
50 the full complexity of medication use patterns. By considering only the timing of drug exposure,  
51 these methods overlook other critical factors such as dose intensity and the chemical and  
52 therapeutic characteristics of the medications involved. This narrow focus limits their applicability,  
53 particularly in scenarios where the interplay between different medications and their specific  
54 attributes is crucial, such as in studies of drug safety and efficacy. Few developments have been  
55 made to approaches which learn from both exposure timing and the chemical and therapeutic  
56 characteristics of the medication(s) used [8]. To the authors' knowledge, no publicly available  
57 software that learns from this combined information to identify real-world prescription drug use  
58 patterns exists.

59 In this paper, we present a novel distance measure explicitly designed for the clustering of  
60 medication use patterns, integrating exposure timing, dose intensity, and medication type based on  
61 Anatomical Therapeutic Clustering (ATC) codes. This distance measure is the foundation of our  
62 Hierarchical Cluster Analysis (HCA) implemented in the `medic()` function in our package `tame`.  
63 HCA is a general and highly adaptable approach to cluster analysis that allows for the clustering of  
64 any data, provided that the user can specify the distance between any pair of observations. We

65 developed this distance measure specifically for the clustering of based on three of the central  
66 characteristics of personal medication use: patterns of medication use by Anatomical Therapeutic  
67 Clustering (ATC) code, exposure timing, and exposure dose. The distance measure allows for flexible  
68 specification of the component parts – ATC code, timing and dose – and their relative importance.  
69 The method avoids unwanted data reduction or oversimplification of information by defining the  
70 distance measure on the person- and medication-specific level. Here, we apply the method to a  
71 Danish nationwide cohort of pregnancies with at least one antidepressant used 0-24 weeks prior to  
72 pregnancy onset in order to map Danish mothers' use of antidepressants leading up to- and during  
73 pregnancy.

## 74 **IMPLEMENTATION**

75 `tame` is implemented in R (R Development Core Team 2022) as a package and requires the following  
76 R packages: `dplyr` ( $\geq 1.1.0$ ), `fuzzyjoin`, `magrittr`, `purrr`, `Rfast`, `rlang`, `stats`, `stringr`,  
77 `tibble`, `tidyr`, `tidyselect`, `Rcpp` ( $\geq 1.0.8$ ). A development version is also available on GitHub  
78 [<https://github.com/Laksafoss/tame>] and collaborators are welcome to fork or make pull requests.  
79 The `tame` package provides methods for clustering medication data by ATC codes, dose and timing,  
80 analysing and illustrating these clusters, and employing these learned clusters to new data in a  
81 similar format. These central functionalities are implemented in the functions ``medic()``,  
82 ``summary()``, and ``employ()``, along with a few supporting functions. The package also includes  
83 a simulated dataset for demonstrating the code.

### 84 **Clustering Analysis**

85 Our medication clustering method, implemented in the ``medic()`` function, utilizes a novel  
86 distance measure within an agglomerative hierarchical cluster analysis (HCA) framework. The  
87 bespoke distance measure drives the clustering process by accurately quantifying the similarities

88 between any two individual-level medication use profiles. The quality and effectiveness of the  
89 clustering hinge on this measure, making it the critical element of our methodology.

90 This distance measure is a composite that integrates multiple dimensions of medication information:  
91 dose intensity, timing of medication and the ATC classification system. **Figure 1** provides an overview  
92 of this method, illustrating how the distance measure is constructed and applied within the  
93 clustering process to group individuals based on their medication use patterns.

94 Difference in two individual-level medication profiles by dose intensity and timing of medication are  
95 measured by a dose trajectory distance measure. This distance measure compares the medication  
96 dose at each timepoint in the study and summarizes across time using the Minkowski distance. The  
97 mathematics behind the method are available in S1, and a mathematical glossary is available in S2

98 The ATC distance measure compares two medications by considering the levels of the medications  
99 ATC code. The distance between two medications is found by identifying the deepest ATC code level  
100 that is shared between the two medications. For example, sertraline *N06AB06* and clomipramine  
101 *N06AA04* are both antidepressants (*N06A*) and are identical at ATC level 3, but sertraline *N06AB06*  
102 and oxycodone *N02AA05* are only identical at ATC level 1, where they share the nervous system main  
103 group (*N*). Thus, the distance between sertraline *N06AB06* and clomipramine *N06AA04* is smaller  
104 than the distance between sertraline *N06AB06* and oxycodone *N02AA05*. Note that if two  
105 medications have the same ATC codes, their distance is 0, and they are considered to be the same  
106 medication under this distance measure.

107 A wide range of parameters allow for the tuning of the dose trajectory distance measure, the ATC  
108 distance measure, and their relative importance. This flexibility ensures that the distance measure  
109 can be adapted to the specific context and research questions, preserving the complexity and  
110 richness of the underlying data. Detailed explanations and discussions of these tuning parameters  
111 and more can be found in S3.

112 While the method – like all clustering methods – is computationally intensive, these demands are  
113 justified by the need for accurate and meaningful clustering based on the detailed distance measure.  
114 For a technical discussion on these aspects of the implementation, see S4.

### 115 `medic()`: Identifying clusters

116 The `medic()` function is the central power house of the `tame` package. This function computes  
117 the distances between all pairs of individuals, runs the hierarchical clustering algorithm, and returns  
118 the clusters. See **Figure 1** for a visual guide to the steps performed by the `medic()` function,  
119 including how it calculates the composite distance measure and applies hierarchical clustering to  
120 group individuals based on their medication use profiles.

---

**Code Chunk 1.** Example of how to cluster medication use data using `medic`. The first example performs a simple clustering based solely on the ATC codes, grouping the `complications` dataset into 3 clusters. The second example performs a more detailed clustering that considers both ATC codes and the timing of exposure (from the first to third trimester). This returns clustering results with 3, 4, and 5 clusters (`k=3:5`), allowing for the exploration of different grouping structures in the data.

```
# Load simulated data
data("complications")

# A simple clustering based only on ATC
clust <- medic(complications, id = id, atc = atc, k = 3)

# A clustering based on both ATC and exposure timing
# returning clusterings with 3, 4, and 5 clusters
clust <- medic(
  complications,
  id = id,
  atc = atc,
  timing = first_trimester:third_trimester,
  k = 3:5
)
```

121

122 The function requires that the user provides a dataset where each row encodes personal medication  
123 patterns of each medication. Thus, a person exposed to 3 medications has 3 rows in the data. In S5  
124 examples of how data might be structured can be found. Columns in this dataset naming the person  
125 identification variable, the medication ATC code variable, and, if available, one or more numerical

126 variables encoding dose and/or exposure trajectory. The user specifies the desired number(s) of  
127 clusters with the function input `k`. Moreover, a number of function parameters can be used to  
128 tune the distance. A full discussion of these tuning parameters can be found in S3.

129

### 130 `summary()` : Summarizing clusters

131 A wide range of cluster summarisation tools are implemented. Summary functions investigates  
132 different aspects of the clustering characteristics and have a corresponding plotting method. The list  
133 of summarisation approaches is given in the code documentation [9], and the latest version at time  
134 of publication can be found in S7. As an example, Figure 2 has been made using these summary tools.

---

**Code Chunk 2.** Examples of how to make summaries of the clustering characteristics. Individual characteristics are summarized with functions like `cluster_frequency()`, `medication_frequency()`, `comedication_count()`, `timing_trajectory()`, and `timing_atc_group()`. Multiple aspects can be summarized using `summary()`, either for specific outputs or all characteristics. Generate a full summary plot for a specific cluster (e.g., `k == 3`) using `plot_summary()`. To simplify or anonymize small groups, apply `summary_crop()` before creating the summary plot.

```
# Summarizing individual aspect of the clustering
clust |> cluster_frequency()
clust |> medication_frequency()
clust |> comedication_count()
clust |> timing_trajectory()
clust |> timing_atc_group()

# Summarizing multiple aspects of the clustering
clust |> summary(outputs = c("cluster_frequency", "timing_trajectory"))
clust |> summary(outputs = "all")

# Making the full summary plot of the clustering with 3 clusters
clust |> plot_summary(only = k==3)

# To simplify or blind small groups apply the `summary_crop()` function
clust |>
  summary() |>
  summary_crop(which = "medication_frequency", top_n = 3) |>
  plot_summary(only = k==5)
```

135

## 136 `employ()` : Applying Clusters to New Data

137 An important functionality of the package is the `employ()` function, which takes an existing  
138 clustering and a new dataset and uses this particular clustering on the new data. Each new individual  
139 is assigned to the closest existing cluster. This functionality enables the learning of the clustering on a  
140 sub-cohort such that this clustering can be applied to the entire cohort. This is especially  
141 advantageous for saving computational time by clustering on a representative sub-cohort and then  
142 generalizing, or when working with a distinct sub-cohort, which should guide the learning of  
143 medication features (e.g., persons with a specific diagnosis or persons exposed to a specific interest  
144 medication). Moreover, this functionality enables easy sharing of learned clusters across studies and  
145 countries.

---

**Code Chunk 3.** Example of how to employ an already learned clustering to new data. The ‘train’ dataset (first 100 entries of complications) is clustered using the `medic()` function, with three clusters (`k = 3`). The resulting model (`clust`) is then applied to the ‘test’ dataset (entries 101–149) using the `employ()` function, allowing for the identification of similar medication patterns in new data.

```
# We have two distinct datasets 'train' and 'test'
train <- complications[1:100,]
test <- complications[101:149,]

# Cluster the medication data 'train'
clust <- medic(train, id = id, atc = atc, k = 3)

# Employ the learned clusters to new data 'test'
employ(clust, test)
```

146

## 147 Installation

148 The tame package is available on *The Comprehensive R Archive Network* (CRAN), and may be installed  
149 by running `install.packages("tame")` in R ≥4.2. Additionally, development versions may be  
150 available on github at <https://github.com/Laksafoss/tame>.

151



## 152 **USE**

153 To demonstrate the use and utility of `tame`, we apply the methodology to the medication use  
154 immediately before- and during pregnancy using a cohort of Danish women with a history of  
155 antidepressant use before pregnancy. We investigate how these medications are used in practice,  
156 and how use is related to redeeming psycholeptics in the first year after pregnancy. Please note that  
157 this study primarily serves as an example of how to use the package.

## 158 **Ethics declaration**

159 The Danish national registries used in this study are protected by the Danish Data Protection Act. No  
160 informed consent nor approval from the Danish Research Ethics Committees were needed for this  
161 study, since only national register data was used. By law, no ethics committee approval is required  
162 for studies only using register-data.

## 163 **Characterizing Antidepressant Use Before and During Pregnancy**

164 We identified all live-born singleton births with a gestational age of at least 36 weeks between 1997  
165 and 2016 in the Danish Medical Birth Registry [10]. Using the Danish National Prescription Registry,  
166 the cohort was restricted to women who redeemed at least one antidepressant within the six  
167 months before pregnancy. To conduct outcome analyses we also linked this cohort to a number of  
168 registers on demographic, socioeconomic and healthcare information; for more on these variables  
169 see S6. The anonymized individual-level data was accessed on Denmark Statistics' researcher  
170 machines on December 12th, 2023.

171 Assuming an exposure of WHO's defined daily dose each day, we estimated the time varying  
172 antidepressant exposure of each individual from 24 weeks before pregnancy until gestational week  
173 36 in the following medication groups: selective serotonin reuptake inhibitors (SSRI; ATC codes  
174 starting with N06AB), serotonin-norepinephrine reuptake inhibitors (SNRI; ATC codes starting with

175 N06AX), and others antidepressants (ATC codes starting with N06AA, N06AF or N06AG). For each  
176 individual and each day, antidepressant use was classified as exposed or unexposed (0/1). A  
177 description and discussion of the tuning parameters chosen for this example may be found in S3.  
178 Seven clusters were used to describe the data.

179 Figure 2 characterizes the clustering of antidepressant medication patterns learned from the data  
180 using `medic()` and then illustrated with `plot_summary()`. In the first column, the  
181 characteristics of the entire population are illustrated, and the following 7 columns display the  
182 characteristics of each cluster, highlighting distinct patterns within the data. Each row illustrates a  
183 different characteristic: number of antidepressants used per person in the cluster, frequency of use  
184 of the 5 most prevalent antidepressant ATC codes in the cluster, average cluster timing of all  
185 antidepressant medications, SSRI use, SNRI use, other antidepressant use, respectively.

186 For the entire study population (column 1), row 1 demonstrates that the majority (76%) of the  
187 mothers take only one antidepressant in the study period, one-fifth are exposed to two  
188 antidepressants, and even fewer (4%) are exposed to three or more antidepressants. In row 2, we  
189 see that four out of five of the most used antidepressants are SSRIs. Rows 3 to 6 show the average  
190 medication exposure trajectory among all medications (row 3), among SSRIs (row 4), among SNRIs  
191 (row 5), and among other antidepressants (row 6). As we are considering a binary exposure in this  
192 example, the average displayed may be interpreted as the percentage of pregnancies exposed at that  
193 particular timepoint. The overall average (row 3) shows that at any given week before the  
194 conception, at least half of the studied women are exposed to one or more antidepressants; then,  
195 during the 12 first weeks of pregnancy, the antidepressant use drops. This pattern is consistent  
196 across all three groups of antidepressants, but the level of use in any given week is different, with  
197 SSRI usage being consistently more frequent than SNRI and other antidepressants (rows 3-6). We  
198 further describe clusters II, III, and IV here, and all clusters in S8.

199 Cluster II – “Sustained use of one SSRI”: The second cluster, with 26% of pregnancies, is almost  
200 exclusively SSRI single drug users. The pregnancies in this cluster has a high level of sustained SSRI  
201 usage with at least 70% of pregnancies being exposed at any time point in the study period, and with  
202 more than 90% of pregnancies being exposed in the weeks 0 to 13.

203 Cluster III – “Concomitant use of different types of antidepressants”: The third largest cluster with  
204 13% of pregnancies studied, is characterized by concomitant drug use of a mix of all 3 classes of  
205 antidepressants. More than 88% of pregnancies are exposed to either SSRI or SNRI or both, while  
206 only 18% of pregnancies are exposed to other antidepressants. The SSRI use frequency remains fairly  
207 stable across the entire exposure period, as opposed to the SNRI use frequency which drops at the  
208 start of the pregnancy.

209 Cluster IV – “Multiple SSRIs used”: Cluster IV, which consists of 11% of pregnancies is characterized  
210 by multiple drug use, with less than 3% using only one drug, almost 88% using 2 antidepressants, and  
211 10% using 3 or more antidepressants. Unlike cluster III, where pregnancies are exposed to a mix of  
212 different types of antidepressants, in this cluster, the exposure is multiple SSRIs.

### 213 **Risk of redeeming psycholeptics within one year of birth according to medication cluster** 214 **membership**

215 To give an example of how to use these learned medication clusters in further analysis, we apply  
216 them in an analysis of the adjusted cumulative incidence of adverse psychiatric post-partum  
217 outcomes. In this example, redemption of psycholeptics (ATC group N05; anti-psychotics N05A,  
218 anxiolytics N05B, and hypnotics and sedatives N05C) in the first year following birth is considered as  
219 the outcome, as it serves as a concrete indicator of psychiatric distress and healthcare utilization,  
220 directly impacting maternal and child well-being.

221 We used stabilised inverse probability of treatment weighting. Weights were calculated as the  
222 inverse odds of being assigned medication cluster I, III, IV, V, VI or VII versus medication cluster II

223 adjusted for confounders (see S8 for the full list) in a multinomial regression model. Cluster II was  
224 chosen as the reference cluster as it is a large cluster (26% of pregnancies) with a simple  
225 interpretation (sustained use of one SSRI throughout the exposure period).

226 Risk ratios and risk differences were then calculated at the 365-day mark. The results of the adjusted  
227 cumulative incidence analysis are shown in Figure 3a, and the estimated risk ratio and risk difference  
228 by medication cluster are shown in Figure 3b.

229 From Figure 3b we see that three clusters have a significantly reduced risk of redeeming psycholeptic  
230 prescriptions within 1 year of birth as compared with cluster II, sustained exposure to one SSRI.  
231 These three clusters are cluster I (“discontinuation of SSRI’s”), cluster V (“discontinuation of SNRI’s”) and  
232 cluster VI (“single use of antidepressants in the other antidepressants group”). Conversely,  
233 cluster III (“multiple medication used across antidepressant groups”) is significantly associated with  
234 an increased risk of redeeming psycholeptics within 1 year of birth as compared with cluster II  
235 (“sustained use of on SSRI”).

236 We can also observe from Figure 3b that neither cluster IV (“multiple SSRI’s used”), nor cluster VII  
237 (“sustained use of SNRI or other-antidepressants”) were significantly associated with a higher risk of  
238 redeeming psycholeptics as compared with cluster II (“sustained use of on SSRI”). All statistical  
239 conclusions were supported on both the risk ratio and risk difference scale.

## 240 **DISCUSSION**

241 The `tame` package implements a novel data-driven learning method for understanding individual-  
242 level medication patterns through hierarchical clustering and provides tools for illustrating and  
243 characterising these clusters. The construction of a distance measure is the cornerstone of any  
244 clustering method, as it dictates the method’s ability to accurately group similar observations and  
245 differentiate dissimilar ones. In machine learning, the quality of a distance measure directly impacts  
246 the success of the model. Our novel distance measure, specifically tailored for medication data,

247 uniquely incorporates the ATC code, exposure timing, and medication dosage, allowing researchers  
248 to fine-tune the relative importance of these factors. This flexibility is crucial for ensuring that the  
249 clusters reflect the true nature of the data and the research objectives. Moreover, a method for  
250 applying existing medication clusters to new medication pattern data has been developed.

251 Here, we demonstrated how `tame` can help identify and narrow down complex trends of  
252 antidepressant use before- and during pregnancy, using a national Danish cohort. In general,  
253 clustering real-world medication data offers a valuable automated search method for detecting  
254 potential safety signals or adverse drug interactions that may not have been previously suspected.  
255 Unlike traditional approaches that rely on specific suspicions or hypotheses, clustering allows for an  
256 exploratory analysis of medication patterns. For example, through clustering, researchers may  
257 discover that a particular cluster, such as medications X and Y frequently taken together, is  
258 associated with an elevated risk of adverse outcomes. This automated identification of medications  
259 and medication combinations that pose potential risks can serve as an early warning system,  
260 prompting further investigation into these specific medication combinations and their effects.

261 Moreover, real-world medication patterns captured through clustering analysis reflect the diverse  
262 medication usage habits of individuals outside controlled clinical trial settings. This real-world  
263 complexity adds depth to our understanding of medication usage and its implications. Additionally,  
264 these patterns can be leveraged for statistical adjustment or stratification in epidemiological studies.  
265 By accounting for these real-world medication patterns, researchers can better control for  
266 confounding factors and obtain more accurate estimates of treatment effects in epidemiological  
267 studies and observational research.

268 When using this method, specifying tuning parameters provides great customizability but require  
269 decisions from the researcher. Thus, tuning the distance measure will still have to be done in  
270 accordance with the understanding of the studied medication and the clinical setting. However,

271 methods for algorithmically optimizing the number of clusters and assisting in the choice of linkage  
272 according to measures of goodness of fit is currently underway.

273 Naturally, clustering personal medication usage according to ATC codes is limited by the ATC  
274 classification system itself. The ATC hierarchy classify according to main therapeutic use or  
275 mechanism of action of the main active ingredient, and as such, encode the main indication of the  
276 drug. However, many medications are used for multiple indications but will only be assigned one ATC  
277 code according to the main indication. This can obscure the full spectrum of a medication's  
278 applications. Moreover, an ATC group may be specified according to mechanism of action, resulting  
279 in groups where the medications have diverse indications, complicating the interpretation of  
280 clustering results. In addition, a chemical substance may be given more than one ATC code if it is  
281 used for two different therapeutic purposes. For a detailed introduction to the construction of  
282 WHO's ATC classification system see [11]. Thus, as the ATC classification system classifies both  
283 according to the therapeutic and the pharmacological aspects of a medication, so does the  
284 classification method presented in this paper. Methods for extending the ATC distance measure to  
285 allow for user defined exceptions or additions to the ATC classification system are in progress. This  
286 extension will allow the user to give all medications with identical active ingredients a smaller  
287 distance regardless of distance in the ATC hierarchy or make combination products more similar than  
288 the ATC hierarchy suggests.

289 In addition, a central feature of hierarchical clustering, and many other clustering methods, is that all  
290 observations are assigned a cluster. Thus, if the data contain many outliers, which in fact are not  
291 comparable with other observation in the data, these will still be placed in clusters. Moreover, the  
292 assignment to a cluster is done in a deterministic way, and the method does not provide uncertainty  
293 estimates for this assignment. These features of clustering lead to less robustness to changes to the  
294 study population. When using `tame`, the `employ()` function can be used to gain some insight into  
295 the extent of this problem in a given dataset through cross validation type strategies.

296 Lastly, it should be noted that clustering methods can be very computationally time and RAM  
297 demanding. This means that we may still be limited in our applications of this method to large  
298 cohorts with wide medication use by our computational power. As discussed in S4, this central  
299 limitation has informed multiple design aspects of the code itself, and computationally intensive  
300 parts of the code are written in C++ or utilize code written in Fortran. This works to ensure a  
301 relatively respectable computational time for our example with just over 33,000 antidepressant  
302 exposed pregnancies of less than 10 minutes on a system with Intel(R) Xeon(R) Gold 6254 CPU @  
303 3.10GHz.

## 304 **Conclusions**

305 In summary, the `tame` package improves on classical approaches to understanding drug exposure by  
306 clustering complex, real-world use patterns which integrate information on timing, dose, and type of  
307 medication. Here, we described an application of how we have used this method to understand  
308 antidepressant use up to and during pregnancy, and then analyse how these learned clusters were  
309 associated with the use of psycholeptics in the first year following birth. In the future, the method  
310 may be used to understand other patterns of prescription drug use and optimize drug safety  
311 surveillance through data driven learning.

## 312 **ACKNOWLEDGMENTS**

313 Authors thank Kim Daniel Jakobsen for his invaluable assistance in the development of the  
314 methodology employed in this study. We would also like to thank Elisabeth O'Regan for her  
315 meticulous attention to detail in formatting and refining the English language of this manuscript.

## 316 **AUTHOR CONTRIBUTIONS**

317 Conceptualising R package functionalities: A.D.L. and J.W. Code development and documentation:  
318 A.D.L. Code testing: A.D.L. Study concept and design: A.D.L., J.W. and A.H.. Data analysis: A.D.L.  
319 Manuscript writing: A.D.L. Critical review: A.D.L., A.H. and J.W. Funding: A.H.

## 320 **DATA AVAILABILITY STATEMENT**

321 Data cannot be shared publicly because of data privacy regulations in Denmark. Applications for data  
322 access should be submitted to Research Services at the Danish Health Data Authority.

## 323 **FUNDING**

324 This work was supported by a grant from the Independent Research Fund Denmark – “Exploring new  
325 ways of classifying medication use in pregnancy for better observational research” (9039-00055B)

## 326 **COMPETING INTERESTS STATMENT**

327 The authors declare no competing interests.



328 **Figure 1.** Overview of the `medic()` function for quantifying and clustering individual-level  
329 medication profiles. The method calculates the similarity between medications using ATC codes and  
330 dosing trajectories, combining these into a comprehensive distance measure that accounts for both  
331 dose intensity and timing. Hierarchical clustering is then applied to group individuals based on these  
332 medication use patterns, revealing similarities in their profiles.

333

334 **Figure 2.** Characteristics of medication use clusters in a cohort of 33,655 Danish pregnant women  
335 with at least one antidepressant prescription within the six months before pregnancy. The figure  
336 illustrates the clustering of these medication patterns, learned from the data using the `medic()`  
337 function and visualized with `plot_summary()`. The first column represents the entire population,  
338 while the subsequent seven columns depict the characteristics of each cluster, revealing distinct  
339 patterns. Each row provides a different characteristic: the first row illustrates the number of  
340 antidepressants used, the second row illustrates the 5 most prevalent antidepressant ATC codes, and  
341 the remaining 4 rows illustrate the average antidepressant exposure timing by anti-depressive type.

342

343 **Figure 3.** Adjusted\* risk of redeeming psycholeptics in the first year following birth according to  
344 medication cluster membership.

345 (A) Adjusted cumulative incidence of redeeming psycholeptics in the first year following birth  
346 according to medication cluster membership. (B) Adjusted risk ratio and risk difference per 100  
347 pregnancies of redeeming psycholeptics one year after birth according to medication cluster  
348 membership.

349 \* Both absolute (A) and relative (B) risks were adjusted for maternal age (<25, 25-29, 30-34, ≥35),  
350 parity (0, 1, 2, ≥3), BMI (<18.5, 18.5-25, 25-30, 30-35, >35), smoking status (non-smoker, stopped  
351 smoking or smoker), family structure (married, single, or living with partner), maternal employment

It is made available under a [CC-BY 4.0 International license](#) .

352 status (employed, employed in a management position, self-employed, or unemployed and receiving  
353 public assistance), maternal level of education (primary, secondary, postsecondary, or vocational  
354 school), location of residence in Denmark (capital region, central region, northern region, Zealand, or  
355 southern region), disposable household income (quartile 1, 2, 3, or 4), and maternal country of origin  
356 (Denmark, Europe (without Denmark), or other), history of psychiatric hospitalizations, history of  
357 self-harm and Charlson comorbidity score  $\geq 1$ .

## REFERENCES

- [1] C. Hurault-Delarue, C. Chouquet, N. Savy, I. Lacroix, A.-B. Beau, J.-L. Montastruc and C. Damase-Michel, "How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women?," *Pharmacoepidemiology and Drug Safety*, vol. 25, no. 7, pp. 770-777, 2016.
- [2] M. E. Wood, A. Lupattelli, K. Palmsten, G. Bandoli, C. Hurault-Delarue, C. Damase-Michel, C. D. Chambers, H. M. E. Nordeng and M. M. H. J. van Gelder, "Longitudinal Methods for Modeling Exposures in Pharmacoepidemiologic Studies in Pregnancy," *Epidemiologic Reviews*, vol. 43, no. 1, pp. 130-146, 2021.
- [3] L. S. Lemon, L. M. Bodnar, W. Garrard, R. Venkataramanan, R. W. Platt, O. C. Marroquin and S. N. Caritis, "Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect," *International Journal of Epidemiology*, vol. 49, no. 2, pp. 648-656, 2019.
- [4] D. Steinley, "K-means clustering: A half-century synthesis," *British Journal of Mathematical and Statistical Psychology*, vol. 59, no. 1, pp. 1-34, 2006.
- [5] C. Genolini, X. Alacoque, M. Sentenac and C. Arnaud, "kml and kml3d: R Packages to Cluster Longitudinal Data," *Journal of Statistical Software*, vol. 65, no. 4, pp. 1-34, 2015.
- [6] C. Genolini, B. Falissard and P. Kiener, "R package version 2.4.6," 2023. [Online]. Available: <https://CRAN.R-project.org/package=kml>.
- [7] C. Proust-Lima, V. Philipps and B. Liqueur, "Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The R Package lcmm," *Journal of Statistical Software*, vol. 78, no. 2, p. 1-56, 2017.
- [8] S. Salvatore, D. Domanska, M. Wood, H. Nordeng and S. Geir Kjetil, "Complex patterns of

concomitant medication use: A study among Norwegian women using paracetamol during pregnancy,” *PLOS ONE*, vol. 12, no. 12, pp. 1-11, 2017.

[9] A. Laksafoss, *tame: Timing, Anatomical, Therapeutic and Chemical Based Medication Clustering*, 2023-02-23.

[10] M. Bliddal, A. Broe, A. Pottegård, J. Olsen og J. Langhoff-Roos, »The Danish Medical Birth Register,« *European Journal of Epidemiology*, årg. 33, nr. 1, pp. 27-36, January 2018.

[11] Health, Norwegian Institute of Public, Last updated: 2022-11-10. [Online]. Available: [https://www.whocc.no/atc/structure\\_and\\_principles/](https://www.whocc.no/atc/structure_and_principles/). [Senest hentet eller vist den 2023-12-19]].






[12] N. T. H. Trinh, T. Munk-Olsen, N. R. Wray, V. Bergink, H. M. E. Nordeng, A. Lupattelli and X. Liu, “Timing of Antidepressant Discontinuation During Pregnancy and Postpartum Psychiatric Outcomes in Denmark and Norway,” *JAMA Psychiatry*, Published online March 08, 2023.

[13] A. Pottegård, S. A. J. Schmidt, H. Wallach-Kildemoes, H. T. Sørensen, J. Hallas and M. Schmidt, “Data Resource Profile: The Danish National Prescription Registry,” *International Journal of Epidemiology*, vol. 46, no. 3, pp. 798-798f, 2017.

[14] M. Bliddal, A. Broe, A. Pottegård, J. Olsen and J. Langhoff-Roos, “The Danish Medical Birth Register,” *European Journal of Epidemiology*, vol. 33, no. 1, pp. 27-36, January 2018.


## Input Data

The `medic()` function processes individual-level medication data, where each row represents a unique medication exposure for a person. The function requires ATC codes and allows for inclusion of dose intensity and timing information. The example dataset depicted in this figure shows Individuals A, B, C, D, and E with varying numbers of medications, each represented with their ATC codes and dose trajectories.




## ATC Distance Measure

The similarity between two medication ATC codes is quantified using the deepest ATC code level shared between the two medications. Distances are encoded as  $\theta_0, \theta_1, \theta_2, \theta_3, \theta_4,$  or  $\theta_5 = 0$ , depending on which ATC level the medications match. For instance, medications with identical first-level ATC codes have a distance  $\theta_1$ , while those matching at the deeper level 4 have a smaller distance  $\theta_4$ . These  $\theta$  values are tunable by the user to better reflect the specific context of the study.



## Dose & Timing Distance Measure

The similarity between two medication dose and timing trajectories is computed using the Minkowski distance. This measure compares the dose intensity at each time point and summarizes the differences across the entire exposure period. It ensures that medications with similar dosing patterns are recognized as more alike, even if their exact doses differ.



## The Distance Measure


The comprehensive distance between two individual-level medication profiles is calculated by integrating both the ATC distance and the dose and timing distance. The formula captures the balance between these two components, allowing customization through the parameters  $\alpha, \beta$  and  $\gamma$  to weigh the relative importance of ATC codes versus dose trajectories. In this example we have used the "average distance measure" formula, which is one of two formulas we have developed for `tame`.


$$d(\text{Individual A}, \text{Individual B}) = \frac{1}{(n \cdot m)^\alpha} \sum \sum ((1 - [\text{ATC Distance}]) (1 - \gamma [\text{Dose \& Timing Distance}]) - 1)^\beta$$


medRxiv preprint doi: <https://doi.org/10.1101/2024.06.24.24309427>; this version posted September 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

## Hierarchical Clustering

The `medic()` function uses agglomerative hierarchical clustering to group individuals based on the distances between their medication use patterns. The clusters reveal similarities in medication profiles, where individuals within the same cluster share closer ATC and dosing trajectory patterns. In this example Individuals A, C, and E form Cluster I, and Individuals B and D form Cluster II, reflecting their medication use similarities.





**A****B**

Cluster		Number of pregnancies	Risk Ratio (95% Conf. Int.)	Risk Difference per 100 pregnancies (95% Conf. Int.)
● Cluster I	"Discontinuation of SSRI's"	11,272	0.83 (0.76 – 0.90)	-2.26 (-3.27 – -1.25)
● Cluster II	"Sustained use of one SSRI"	8,586	1 (Ref)	0 (Ref)
● Cluster III	"Multiple medication used across anti-depressant groups"	4,418	1.31 (1.18 – 1.43)	3.98 (2.53 – 5.43)
● Cluster IV	"Multiple SSRI's used"	3,563	1.08 (0.96 – 1.19)	1.03 (-0.45 – 2.50)
● Cluster V	"Discontinuation of SNRI's"	3,241	0.75 (0.65 – 0.84)	-3.27 (-4.60 – -1.93)
● Cluster VI	"Single use of antidepressants in the other anti-depressants group"	1,324	0.81 (0.64 – 0.97)	-2.54 (-4.78 – -0.29)
● Cluster VII	"Sustained use of SNRI or other-antidepressants"	1,251	1.17 (0.91 – 1.42)	2.17 (-1.14 – 5.49)